Page 10 - Aurobindo Pharma

Aurobindo's strong European, US prospects keeping analysts bullish

As the pricing pressure in US generics market recedes, the company is also expected to fair well, say analysts, who see growth impetus coming from its recent acquisitions in the US and Europe

Aurobindo Pharma acquires 7 oncology products from US company for $300 mn

The product portfolio is expected to generate a revenue of around $100 million for first 12 months after completion of the transaction for Aurobindo

Lacunae in Aurobindo Pharma's Medak facility in Andhra, says FDA report

Besides, the report said preparative apparel was not worn as necessary to protect drug products from contamination

Aurobindo acquires Apotex Inc's biz in 5 European countries for 74 mn euros

BS ReporterHyderabad, 14 July: Aurobindo Pharma Limited announced today that its step-down subsidiary Agile Pharma B V(Netherlands ) signed a definitive agreement to acquire from Canadian pharmaceuticals company Apotex International Inc. its commercial operations and certain supporting infrastructure in five European countries for Euro 74 million(Rs 5.93 billion) in an all cash deal. The company expects to close the transaction in 3-6 months.The acquisition is in line with Aurobindo's strategy to strengthen and grow its European business and to expand in Eastern Europe, the company said.The acquisition includes a portfolio of over 200 prescription drugs and 88 OTC products and an additional pipeline of over 20 products which are expected to be launched over the next two years, besides a manufacturing facility in Leiden the Netherlands, with capabilities across manufacturing and packaging and capacity of 1.8 billion tablets per annum.With the acquisition of Apotex Inc's commercial ...

Aurobindo Pharma: US sales, European biz suggest drivers are in place

The acquired business is estimated to have annual sales of euro 130 million, according to analysts, and will add to Aurobindo's prospects in Europe

Aurobindo acquires Apotex's commercial operations in 5 European countries

Aurobindo Pharma had inked a binding agreement on July 14, 2018, to acquire five of Apotex' European businesses

Aurobindo Pharma's Q3 profit surges 19.69% to Rs 712 crore on robust sales

Revenues from operations increased 21.5 percent to 5,269.7 crore during the quarter under review as compared to Rs 4336.1 crore in the year ago period

Aurobindo Pharma's Q3 profit surges 19.69% to Rs 712 crore on robust sales

'We have delivered a robust revenue growth of 22%', said Aurobindo Pharma MD N Govindarajan

Aurobindo Pharma to acquire oncology products from US-based firm in $300 mn

Acrotech will be acquiring the product portfolio on a debt free and cash free basis, Aurobindo Pharma Ltd said in a regulatory filing

Aurobindo expects Sandoz buy to make it second-largest generics firm in US

The Hyderabad-based company is at fifth place in prescription sales, next to Indian counterpart Lupin, in the US

Aurobindo Pharma USA recalls 80 lots of blood pressure drug from US

To date, Aurobindo Pharma USA Inc has not received any reports of adverse events related to this recall, the company said

Aurobindo's injectable business grows 8% year-on-year to $50 mn in Q2

Analysts feel R&D costs are set to rise as a result of injectables and biosimilars focus

Aurobindo Pharma gets final approval from USFDA to market anaesthesia drug

The approved product is a generic equivalent of Organon's Norcuron Injection

Aurobindo Pharma gets USFDA nod to market potassium chloride pills in US

The potassium chloride tablets are for treating hypokalemia, a condition wherein there is a drop in the potassium-level in the blood

Aurobindo Pharma arm inks pact with Shandong Luoxin to form JV in China

The JV will also undertake contract manufacturing for non-nebuliser inhaler products

Aurobindo named in a lawsuit for selling adulterated irbesartan products

In October, Aurobindo Pharma announced a voluntary recall of 22 batches of irbesartan due to the detection of trace amounts of NDEA

Aurobindo Pharma hits 52-week high; up 56% in six months

The stock hit a 52-week high of Rs 830, up 3%, surging 55% in past six months, as compared to 3% rise in the S&P BSE Sensex.

Improving margins, reducing debt key challenges for Aurobindo Pharma

While revenue growth is expected to be strong, improving margins and reducing debt could be challenging

Aurobindo Pharma to launch oncology, respiratory products in US by 2021

The company is also planning to launch first set of biosimilars and vaccines in growth markets during this time, Aurobindo Pharma said in an investor presentation

Aurobindo expects drug filing opportunities in US to stay for another 5 yrs

The senior management of Aurobindo said they are looking at launching the Oncology products in the US market by the end of this year